Therapeutic treatment strategies for the management of onychomycosis: a patent perspective

References

• Shivakumar HN, Juluri A, Desai BG, et al. Ungual and transungual drug delivery. Drug Dev Ind Pharm. 2012;38(8):901–911. doi: 10.3109/03639045.2011.637931
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol. 2019;80(4):835–851. doi: 10.1016/j.jaad.2018.03.062
   PubMed Web of Science ®Google Scholar
• Nagpal M, Kaur M. Nanomaterials for skin antifungal therapy: an updated review. J Appl Pharm Sci. 2021;11:15–25.
   Google Scholar
• Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43(4):641–648. doi: 10.1067/mjd.2000.107754
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3):415–429. doi: 10.1128/CMR.11.3.415
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis: treatment, quality of life, and economic issues. Am J Clin Dermatol. 2000;1:19–26. doi: 10.2165/00128071-200001010-00002.
   PubMedGoogle Scholar
• Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol. 1994;31(3):S78–S81. doi: 10.1016/S0190-9622(08)81274-1
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ryder JE, Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin. 2003;21(3):481–489. doi: 10.1016/S0733-8635(03)00025-1
   PubMed Web of Science ®Google Scholar
• Khengar RH, Jones SA, Turner RB, et al. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers. Pharm Res. 2007;24(12):2207–2212. doi: 10.1007/s11095-007-9368-3
   PubMed Web of Science ®Google Scholar
• Elkeeb R, AliKhan A, Elkeeb L, et al. Transungual drug delivery: Current status. Int J Pharm. 2010;384(1–2):1–8. doi: 10.1016/j.ijpharm.2009.10.002
   PubMedGoogle Scholar
• Agrawal V, Patel R, Patel M. Design, characterization, and evaluation of efinaconazole loaded poly(D, L-lactide-co-glycolide) nanocapsules for targeted treatment of onychomycosis. J Drug Deliv Sci Technol. 2023;80:104157. doi: 10.1016/j.jddst.2023.104157.
   Web of Science ®Google Scholar
• Dhamoon RK, Popli H, Gupta M. Novel drug delivery strategies for the treatment of onychomycosis. Pharm Nanotechnol. 2019;7:24–38.
   PubMedGoogle Scholar
• Alam G, Singh MP, Singh A, et al. Trans-ungual drug transport: advancement and challenges. J Pharm Res. 2012;5:2574–2579.
   Google Scholar
• Murdan S. Drug delivery to the nail following topical application. Int J Pharm. 2002;236(1–2):1–26. doi: 10.1016/S0378-5173(01)00989-9
   PubMed Web of Science ®Google Scholar
• Fokias K, Dierckx L, Van de Voorde W, et al. Age determination through DNA methylation patterns in fingernails and toenails. Forensic Sci Int Genet. 2023;64:102846. doi: 10.1016/j.fsigen.2023.102846
   PubMed Web of Science ®Google Scholar
• Garson JC, Baltenneck F, Leroy F, et al. Histological structure of human nail as studied by synchrotron X-ray microdiffraction. Cell Mol Biol (Noisy-le-Grand, Fr). 2000;46:1025–1034.
   PubMed Web of Science ®Google Scholar
• Krönauer C, Gfesser M, Ring J, et al. Transonychial water loss in healthy and diseased nails. Acta Derm Venereol. 2001;81(3):175–177. doi: 10.1080/000155501750376249
   PubMed Web of Science ®Google Scholar
• De Berker DAR, André J, Baran R. Nail biology and nail science. Int J Cosmet Sci. 2007;29(4):241–275. doi: 10.1111/j.1467-2494.2007.00372.x
   PubMedGoogle Scholar
• Fanti PA, Tosti A, Cameli N, et al. Nail matrix hypergranulosis. Am J Dermatopathol. 1994;16(6):607–610. doi: 10.1097/00000372-199412000-00006
   PubMed Web of Science ®Google Scholar
• Park S, Yun S-J. Acral Melanocytic Neoplasms: a comprehensive review of acral nevus and acral melanoma in Asian perspective. Dermatopathology. 2022;9(3):292–303. doi: 10.3390/dermatopathology9030035
   PubMed Web of Science ®Google Scholar
• Achtfn G, Parent D. The normal and pathologic nail. Int J Dermatol. 1983;22(10):556–565. doi: 10.1111/j.1365-4362.1983.tb02124.x
   PubMed Web of Science ®Google Scholar
• Chang P. Diagnosis using the proximal and lateral nail folds. Dermatol Clin. 2015;33(2):207–241. doi: 10.1016/j.det.2014.12.004
   PubMed Web of Science ®Google Scholar
• Fleckman P. Anatomy and Physiology of the nail. Dermatologic clinics. 2021;3(3):373–381.
   Google Scholar
• De Berker D. Nail anatomy. Clin Dermatol. 2013;31(5):509–515. doi: 10.1016/j.clindermatol.2013.06.006
   PubMed Web of Science ®Google Scholar
• Thampi L, Gini EJ. In-vitro and in-vivo characterization of anti-onychomycotic transungual patches-a systematic review. Res J Pharm Technol. 2023;16(3):1527–1532. doi: 10.52711/0974-360X.2023.00250
   Google Scholar
• Bhairy S, Momin A, Pednekar M, et al. A note on the Current status of the trans-ungual delivery of poorly soluble drugs at a glance: formulation perspective. Asian J Res Infect Dis. 2023;12:1–21. doi: 10.9734/ajrid/2023/v12i3244
   Google Scholar
• Šveikauskaite I, Briedis V. Potential of naftifine application for transungual delivery. Molecules. 2020;25(13):3043. doi: 10.3390/molecules25133043
   PubMed Web of Science ®Google Scholar
• Gupta I, Adin SN, Aqil M, et al. Investigation on utility of some novel terpenes on transungual delivery of terbinafine for the management of onychomycosis. Dermatology Pract Concept. 2022;12(4):e2022202.
   Google Scholar
• Roja P, Eswarudu M, Ravishankar P, et al. Formulation and evaluation of nail drug delivery system of anti fungal drug. Asian J Pharm Res Dev. 2022;10:59–76. doi: 10.22270/ajprd.v10i6.1189
   Google Scholar
• Thatai P, Sapra B. Transungual delivery: deliberations and creeds. Int J Cosmet Sci. 2014;36(5):398–411. doi: 10.1111/ics.12142
   PubMed Web of Science ®Google Scholar
• Brown MB, Khengar RH, Turner RB, et al. Overcoming the nail barrier: a systematic investigation of ungual chemical penetration enhancement. Int J Pharm. 2009;370(1–2):61–67. doi: 10.1016/j.ijpharm.2008.11.009
   PubMedGoogle Scholar
• Thomas J, Jacobson GA, Narkowicz CK, et al. REVIEW ARTICLE: toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519. doi: 10.1111/j.1365-2710.2009.01107.x
   PubMed Web of Science ®Google Scholar
• Pal M, Dave P, Dave K, et al. Etiology, clinical spectrum, epidemiology, New developments in diagnosis and therapeutic management of Onychomycosis: an update. Am J Microb Res. 2023;11:19–24. doi: 10.12691/ajmr-11-1-3
   Google Scholar
• Tyagi SN, Kaur R, Kaur R, et al. A study of etiology and epidemiology of onychomycosis from a tertiary care hospital in North India. Int J Res Med Sci. 2021;9(2):559. doi: 10.18203/2320-6012.ijrms20210442
   Google Scholar
• Sharma S, Chopra H, Pahwa R, et al. Novel transungual drug delivery system for treating onychomycosis. Int J Surg. 2023;Publish Ahead of Print:2145–2147. Publish Ahead of Print doi: 10.1097/JS9.0000000000000041
   Google Scholar
• Bitew A, Wolde S. Prevalence, risk factors, and spectrum of fungi in patients with onychomycosis in Addis Ababa, Ethiopia: a prospective study. J Trop Med. 2019;2019:1–6. doi: 10.1155/2019/3652634.
   Web of Science ®Google Scholar
• Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972–1990. doi: 10.1111/jdv.16394
   PubMed Web of Science ®Google Scholar
• Grover C, Khurana A. Onychomycosis: newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereol Leprol. 2012;78:263–270. doi: 10.4103/0378-6323.95440.
   PubMed Web of Science ®Google Scholar
• Tosti A, Hay R, Arenas-Guzmán R. Patients at risk of onychomycosis – risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005;19(s1):13–16. doi: 10.1111/j.1468-3083.2005.01282.x
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Steingrímsson Ö. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venerol. 2004;18(1):48–51. doi: 10.1111/j.1468-3083.2004.00851.x
   PubMed Web of Science ®Google Scholar
• Chularojanamontri L, Pattanaprichakul P, Leeyaphan C, et al. Overall prevalence and prevalence compared among psoriasis treatments of onychomycosis in patients with nail psoriasis and fungal involvement. Biomed Res Int. 2021;2021:1–12. doi: 10.1155/2021/9113418
   PubMedGoogle Scholar
• Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013;31(5):544–554. doi: 10.1016/j.clindermatol.2013.06.011
   PubMed Web of Science ®Google Scholar
• De Sá DC, Lamas APB, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15:17–36. doi: 10.1007/s40257-013-0056-2.
   PubMed Web of Science ®Google Scholar
• Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol. 2010;28(2):151–159. doi: 10.1016/j.clindermatol.2009.12.006
   PubMed Web of Science ®Google Scholar
• Gupta AK, Paquet M. Improved efficacy in onychomycosis therapy. Clin Dermatol. 2013;31(5):555–563. doi: 10.1016/j.clindermatol.2013.06.010
   PubMed Web of Science ®Google Scholar
• Gunt HB, Kasting GB. Effect of hydration on the permeation of ketoconazole through human nail plate in vitro. Eur J Pharm Sci. 2007;32(4–5):254–260. doi: 10.1016/j.ejps.2007.07.009
   PubMed Web of Science ®Google Scholar
• Bellmann T, Luber R, Kischio L, et al. Bacterial nanocellulose patches as a carrier for hydrating formulations to improve the topical treatment of nail diseases. Int J Pharm. 2022;628:122267. doi: 10.1016/j.ijpharm.2022.122267
   PubMedGoogle Scholar
• Kobayashi Y, Miyamoto M, Morimoto KSY. Enhancing effect of N-acetyl-l-cysteine or 2-mercaptoethanol on the in vitro permeation of 5-fluorouracil or tolnaftate through the human nail plate. Chem Pharm Bull. 1984;32:685–691.
   Google Scholar
• Malhotra GG, Zatz JL. Investigation of nail permeation enhancement by chemical modification using water as a probe. J Pharm Sci. 2002;91(2):312–323. doi: 10.1002/jps.10058
   PubMed Web of Science ®Google Scholar
• Swenholt KC Nail fungus treatment and composition. US20160235847A1. 2016.
   Google Scholar
• Shanbhag PP, Jani U. Drug delivery through nails: present and future. New Horizons Transl Med. 2017;3(5):252–263. doi: 10.1016/j.nhtm.2017.01.002
   Google Scholar
• Capriotti J, Capriotti K Veloce Biopharma LLC, assignee. Antifungal compositions for the treatment of skin and nails. USOO9408867B2. 2016
   Google Scholar
• Vejnovic I, Simmler L, Bentz G. Investigation of different formulations for drug delivery through the nail plate. Int J Pharm. 2010;386(1–2):185–194. doi: 10.1016/j.ijpharm.2009.11.019
   PubMedGoogle Scholar
• Gallardo-Villagr M, Paulus L, Leger DY, et al. Dimethyl sulfoxide: a bio-friendly or bio-hazard chemical? The effect of DMSO in human fibroblast-like synoviocytes. Molecules. 2022;27(14):4472. doi: 10.3390/molecules27144472
   PubMed Web of Science ®Google Scholar
• Singh A, Singh P, Dingemans G, et al. Evaluation of DermaGenius ® resistance real-time polymerase chain reaction for rapid detection of terbinafine-resistant Trichophyton species. Mycoses. 2021;64(7):721–726. doi: 10.1111/myc.13271
   PubMed Web of Science ®Google Scholar
• Lindahl A, Moberg Pharma AB Antifungal composition. US008952070B2. 2015.
   Google Scholar
• Cutrín-Gómez E, Conde-Penedo A, Anguiano-Igea S, et al. Optimization of drug permeation from 8 % ciclopirox cyclodextrin/poloxamer-soluble polypseudorotaxane-based nail lacquers. Pharmaceutics. 2020;12(3):231. doi: 10.3390/pharmaceutics12030231
   PubMed Web of Science ®Google Scholar
• Šveikauskait˙ I, Pockeviˇcius A, Briedis V. Potential of chemical and physical enhancers for transungual delivery of amorolfine hydrochloride. Materials. 2019;12(7):1028. doi: 10.3390/ma12071028
   PubMed Web of Science ®Google Scholar
• Rockhill T, Beeson WH; Ad Lunam Labs Inc A. Excipient system for topical delivery of pharmaceutical agents. US 20190247508A1. 2019.
   Google Scholar
• Bornstein E, Joyce A. A seven-year human data analysis (2008-2015) of a near- infrared laser system for the treatment of onychomycosis. Curr Trends Microbiol. 2016;10:1–10.
   Google Scholar
• Willers C Topical pharmaceutical compositions comprising terbinafide and urea. EP 2 664 327 A1. 2013.
   Google Scholar
• Lazardi K, Urbina JA, Souza WDE. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (schizotrypanum) cruzi. Antimicrob Agents Chemother. 1990;34(11):2097–2105. doi: 10.1128/AAC.34.11.2097
   PubMed Web of Science ®Google Scholar
• Pan M, Heinecke G, Bernardo S, et al. Urea: a comprehensive review of the clinical literature. Dermatol Online J. 2013;19(11). doi: 10.5070/D31911020392
   PubMedGoogle Scholar
• Brehove JE Topical application for treating toenail fungus. US006878365B2. 2005.
   Google Scholar
• Bseiso EA, Nasr M, Sammour OA, et al. Novel nail penetration enhancer containing vesicles “nPevs” for treatment of onychomycosis. Drug Deliv. 2016;23(8):72813–72819. doi: 10.3109/10717544.2015.1099059
   Web of Science ®Google Scholar
• Puri V, Froelich A, Shah P, et al. Quality by Design guided development of polymeric nanospheres of terbinafine hydrochloride for topical treatment of onychomycosis using a nano-gel formulation. Pharmaceutics. 2022;14(10):2170. doi: 10.3390/pharmaceutics14102170
   PubMed Web of Science ®Google Scholar
• Wang F, Yang P, Choi JS, et al. Cross-linked fluorescent supramolecular nanoparticles for intradermal controlled release of antifungal drug - a therapeutic approach for onychomycosis. ACS Nano. 2018;12:6851–6859. doi: 10.1021/acsnano.8b02099
   PubMed Web of Science ®Google Scholar
• Verma S, Utreja P. Vesicular nanocarrier based treatment of skin fungal infections: potential and emerging trends in nanoscale pharmacotherapy. Asian J Pharm Sci. 2018;14(2):117–129. doi: 10.1016/j.ajps.2018.05.007
   PubMed Web of Science ®Google Scholar
• Patel MM, Vora ZM. Formulation development and optimization of transungual drug delivery system of terbinafine hydrochloride for the treatment of onychomycosis. Drug Deliv Transl Res. 2016;6(3):263–275. doi: 10.1007/s13346-016-0287-x
   PubMed Web of Science ®Google Scholar
• Tuncay Tanrıverdi S, Hilmioğlu Polat S, Yeşim Metin D, et al. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation. J Liposome Res. 2015;2104:1–11. doi: 10.3109/08982104.2015.1067892
   Google Scholar
• Kumar D, Biosciences V, Pandit V, et al. An insight to pullulan: a biopolymer in pharmaceutical approaches. Int J Basic Appl Sci. 2012;1(3):202–219. doi: 10.14419/ijbas.v1i3.101
   Google Scholar
• Niedermeyer WH; ATTOSTAT Inc A. Nanoparticle compositions and methods for treating onychomychosis. US010201571B2.2019.
   Google Scholar
• Lang-Fugmann SI Antimycotic nail polish formulations comprising substituted 2-aminothiazoles as an active substance. US 20070059261A1. 2007.
   Google Scholar
• Khoee S, Yaghoobian M. Niosomes: a novel approach in modern drug delivery systems. Netherlands: Nanostructures Drug Deliv. Elsevier Inc.; 2018.
   Google Scholar
• Nagpal S, Goyal AN Formulation and evaluation of itraconazole loaded niosomal gel for the treatment of onychomycosis. InPatent 3107DE2013A.2015.
   Google Scholar
• Maley JC Treatment modality and method for fungal nail infection. USOO6921529B2. 2005.
   Google Scholar
• Ahmed EM. Hydrogel: preparation, characterization, and applications: a review. J Adv Res. 2015;6:105–121. doi: 10.1016/j.jare.2013.07.006.
   PubMed Web of Science ®Google Scholar
• Baswan S, Kasting GB, Li SK, et al. Understanding the formidable nail barrier: a review of the nail microstructure, composition and diseases. Mycoses. 2017;60(5):284–295. doi: 10.1111/myc.12592
   PubMed Web of Science ®Google Scholar
• Krainbring VG; Ncp newcare products GmbH, assignee. Composition for treating onychomycosis. US011439593B2. 2022.
   Google Scholar
• Heuschkel S, Goebel A, Neubert RH. Microemulsions — modern colloidal carrier for dermal and transdermal drug delivery. Wiley Intersci. 2008;97:603–631. doi: 10.1002/jps.20995.
   Google Scholar
• Fabi SG. Noninvasive skin tightening: focus on new ultrasound techniques. Clin Cosmet Investig Dermatol. 2015;47–52. doi: 10.2147/CCID.S69118
   PubMedGoogle Scholar
• de Guertchin LO. Surfactants: classification. InHandbook of detergents, part a 1999. Vol. Part. A: CRC Press; 1999. p. 7–46.
   Google Scholar
• Cumbie WE, Juanarena DB, Cumbie William E, et al. Phototherapy treatment and device for infections, diseases, and disorders. US 2009.0143842A1. 2009.
   Google Scholar
• Murdan S. Nail disorders in older people, and aspects of their pharmaceutical treatment. Int J Pharm. 2016;512(2):405–411. doi: 10.1016/j.ijpharm.2016.05.022
   PubMedGoogle Scholar
• Rajendra VB, Baro A, Kumari A, et al. Transungual drug delivery: an overview. J Appl Pharm Sci. 2012;2:203–209.
   Google Scholar
• Wohlrab W, Wellner K; Roehm pharma GmbH A. Nail lacquer for the treatment of onychomycosis. US005.346692A. 1994. 1994.
   Google Scholar
• Coubetergues H, Voisard JJ; Pierre Fabre Dermo Cosmetique SA, assignee. Kit for the treatment of onychomycosis. US 2011 0137269A1.2011.
   Google Scholar
• Chaudhuri B, Chim MB. BPI. Topical formulations for the treatment of nail fungal diseases. USOO6143794A. 2000.
   Google Scholar
• Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol. 2000;43(4):S96–102. doi: 10.1067/mjd.2000.109068
   PubMed Web of Science ®Google Scholar
• Kiran RS, Shekar BC, Vishnu P, et al. Ungual drug delivery system of ketoconazole nail lacquer. Int J Appl Pharm. 2010;4:17–19.
   Google Scholar
• Celleno L. Topical urea in skincare: a review. Dermatol Ther. 2018;31(6):1–5. doi: 10.1111/dth.12690
   Web of Science ®Google Scholar
• Alkhatib HS, Sakr A. Optimization of methacrylic acid ester copolymers blends as controlled release coatings using response surface methodology. Pharm Dev Tevhnol. 2003;8(1):87–96. doi: 10.1081/PDT-120017527
   PubMed Web of Science ®Google Scholar
• Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin Pharmacother. 2012;13(8):1131–1142. doi: 10.1517/14656566.2012.681779
   PubMed Web of Science ®Google Scholar
• Kline-Schoder A, Le Z, Zderic V. Ultrasound-enhanced drug delivery for treatment of onychomycosis. J Med Ultrasound. 2018;37(7):1743–1752. doi: 10.1002/jum.14526
   Google Scholar
• Kumar N, Saini BK, Kaur R. A nontoxic ionic liquid composition for the delivery of biological macromolecular anions across the skin barrier. Pharmaceutical Patent Analyst. 2021;10:191–194. doi: 10.4155/ppa-2021-0012.
   PubMed Web of Science ®Google Scholar
• Enemaerke J I\. Flash lamp method for treating onychomycosis. US 2013 0172961A1. 2013 Jul 4.
   Google Scholar
• Vreman HJ, Wong RS, Stevenson DK. Phototherapy: current methods and future directions. InSeminars Perinatol. 2004;28:326–333. doi: 10.1053/j.semperi.2004.09.003.
   PubMed Web of Science ®Google Scholar
• Karell ML, Karell ML Laser apparatus for making holes and etchings. US005947956A. 1999.
   Google Scholar
• Venkateshwaran S, Quan D Watson Pharmaceuticals Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis. USOO6727401B1. 2004.
   Google Scholar
• Santos KKA, Matias EFF, Tintino SR, et al. Enhancement of the antifungal activity of antimicrobial drugs by Eugenia uniflora L. J Med Food. 2013;16(7):669–671. doi: 10.1089/jmf.2012.0245
   PubMed Web of Science ®Google Scholar
• Chen C, Long L, Zhang F, et al. Antifungal activity, main active components and mechanism of curcuma longa extract against fusarium graminearum. PLoS One. 2018;13(3):1–19. doi: 10.1371/journal.pone.0194284
   Web of Science ®Google Scholar
• Veiga FF, Gadelha MC, Silva MRT, et al. Propolis extract for onychomycosis topical treatment: from bench to clinic. Front Microbiol. 2018;9:1–13. doi: 10.3389/fmicb.2018.00779
   PubMed Web of Science ®Google Scholar
• Pollard TD, Bonetti M, Day A, et al. Printing drugs onto nails for effective treatment of onychomycosis. Pharmaceutics. 2022;14(2):1–16. doi: 10.3390/pharmaceutics14020448
   Web of Science ®Google Scholar
• Kerai LV, Hilton S, Murdan S. UV-curable gel formulations: potential drug carriers for the topical treatment of nail diseases. Int J Pharm. 2015;492(1–2):177–190. doi: 10.1016/j.ijpharm.2015.07.020
   PubMed Web of Science ®Google Scholar
• Zaki AM, Abdo HM, Ebadah MA, et al. Fractional CO2 laser plus topical antifungal versus fractional CO2 laser versus topical antifungal in the treatment of onychomycosis. Dermatol Ther. 2020;33(1):1–7. doi: 10.1111/dth.13155
   Web of Science ®Google Scholar